Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Spinal Cord Injuries, Spinal Cord Diseases
Interventions: Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training, Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training, Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training; Device · Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Urinary Bladder Cancer
Interventions: gemcitabine + docetaxel; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Invasive Candidiasis
Interventions: Preemptive Therapy with Anidulafungin, Empiric antifungal therapy based on physician discretion.; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions: Vofatamab, Docetaxel, Placebo; Drug
Lead sponsor: Rainier Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Gilbert, Arizona • Goodyear, Arizona • Duarte, California + 8 more

Conditions: Liver Cancer
Interventions: Not listed
Lead sponsor: Pathfinder Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Lumbar Spine Stenosis Central Canal
Interventions: Percutaneous Lumbar Decompression, Sham lumbar decompression; Device
Lead sponsor: Napa Pain Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Napa, California

Conditions: Major Depressive Disorder
Interventions: NEST-1 (NeoSync EEG Synchronized TMS), SHAM; Device
Lead sponsor: Wave Neuroscience; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 15 more

Conditions: Non-Muscle Invasive Bladder Carcinoma
Interventions: BCG Solution, Best Practice, Cystoscopy, Home Health Encounter, Survey Administration; Biological · Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Bladder Cancer
Interventions: N-803 and BCG, N-803; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 28
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex, Radiologic Imaging Procedure, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • St Louis, Missouri

Conditions: Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia, Bacteremia
Interventions: UllCORE BSI Test; Diagnostic Test
Lead sponsor: Deepull Diagnostics S.L.; Industry
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Orange, California • Tampa, Florida • Baltimore, Maryland + 7 more

Conditions: Sprain of Ankle
Interventions: Platelet rich plasma injection, Placebo Comparator: Placebo/Standard of Care; Procedure
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: Erdafitinib Intravesical Delivery System; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more

Conditions: Blood Loss, Surgical, Coagulation Disorder
Interventions: Reltodecacog alfa, Usual Pharmacological Care; Drug
Lead sponsor: VarmX B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 19
States / cities: Chandler, Arizona • Phoenix, Arizona • Stanford, California + 14 more

Conditions: Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
Interventions: Veronate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 3 Days to 5 Days
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 85
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 71 more

Conditions: Body Fat Disorder
Interventions: The Zeltiq System; Device
Lead sponsor: Zeltiq Aesthetics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Frontotemporal Dementia
Interventions: Transcranial Alternating Current Stimulation (tACS), Sham Transcranial Alternating Current Stimulation (sham tACS); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder Neoplasms
Interventions: Mycobacterial cell wall-DNA complex; Drug
Lead sponsor: Bioniche Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 20
States / cities: Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more

Conditions: Morbid Obesity, Hernia, Colorectal Cancer, Laparoscopy
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Muscle Invasive Bladder Cancer
Interventions: AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more

Conditions: Primary Open Angle Glaucoma
Interventions: Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane; Drug
Lead sponsor: Center for Sight Las Vegas; Other
Eligibility: 40 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Esophageal Carcinoma
Interventions: Botulinum Toxin Type A, Esophagectomy, Quality-of-Life Assessment; Biological · Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: TARA-002; Biological
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 44
States / cities: Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 38 more

Search by objective public record fields.

SCI Acute Intermittent Hypoxia and Non-Invasive Spinal Stimulation Combined With Gait Training

Intravesical Gem/Doce in Patients With NMIBC

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures

Comparative Study of Sham Versus Mild® Procedure in Patients Diagnosed With Symptomatic Lumbar Central Canal Stenosis

Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder

Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test

Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature

Gamma-Induction in FrontoTemporal Dementia Trial

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Minimally Invasive Surgery (MIS) Database for the Purpose of Research

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer